The study, published in the Clinical Journal of Pain, compared the use of short and long acting opioids. This study is the first to show a significant difference in the effects of long-acting and short-acting opioids.
The 81 men who participated in the study were on a stable dose of an opioid medication for at least three months. Seventy-four percent of the men on long-acting opioids had low testosterone levels as compared to 34 percent of the men using short-acting opioids.
More Articles on Pain Management:
Advanced Pain Care in Texas Hires Dr. Ajay Suman
FDA Advisory Panel Approves Greater Restriction of Vicodin, Other Drugs
EIMindA, Purdue Pharma to Collaborate on Pain Management Research
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
